The PD-1 plus TRAC KO anti-CD19 CAR T study demonstrated 15/16 overall response, 11/16 CR, no GVHD, 2/16 G3-4 ICANS, and prevalent G3 or above cytopenia (G3 or above: 9/16 neutropenia, 11/16 thrombocytopeia, and 8/16 anemia) [152]. The gene discussed is CD19; the disease is graft versus host disease.